Radiant Pharmaceuticals Launches Monoclonal Antibodies for Patients

The global pandemic infection is once again on the rise. At the same time, the number of patients suffering from covid-19 in Bangladesh is increasing at an alarming rate, reports a press release.

In this context, the effective treatment of high-risk covid patients is monoclonal, a drug approved worldwide by the United Kingdom's Medicines and Healthcare Products Regulatory Authority (MHRA) and Japan, and by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 

Casirivimab & Imdevimab monoclonal antibody injection by F. Hoffmann-La Roche Ltd, Switzerland has recently been approved by the Department of Drug Administration in Bangladesh for emergency marketing of high-risk corona patients.

On Wednesday (January 12), Radiant Pharmaceuticals Limited organized a scientific seminar on monoclonal antibodies. In this seminar organized at Hotel Intercontinental in the capital, the eminent doctors of the country gave important discussions about the present and future medical methods.

With the use of this drug and the provision of proper medical care, the condition of a number of high-risk corona patients has been alleviated before it became critical and the risk of death has been reduced. As a result, hospital admissions of covid patients using those antibodies have dropped by about 70 percent.

Clinical benefits

1. The use of Casirivimab and Imdevimab reduces coronavirus symptoms and viral infections within three to five days.
2. This drug is tolerable in the human body without any additional safety instructions. It works precisely and the chances of side effects from using this antibody are low.
3. Two different antibodies work without conflict with each other at the spike protein receptors of the coronavirus. As a result, due to the protection given by the antibody, the virus cannot take on any other mutation/variant.
4. The application of these antibodies reduces the risk of symptomatic covid patients by about 81% and the risk of death by about 70%.
   
5. Even after receiving two doses of the vaccine, about 16% of patients are re-infected with corona, who are at higher risk of dying. Good results have been found in the application of Casirivimab and Imdevimab in such patients.

Recently, the Department of Drug Administration in Bangladesh has approved Casirivimab and Imdevimab for use in the treatment of high-risk corona patients and for emergency marketing. Following this, Radiant Pharmaceuticals Limited has been successfully importing these medicines into a cold chain system to ensure the quality of these medicines in Bangladesh.

This initiative has brought a new weapon among physicians to combat the Corona pandemic, the use of which has significantly improved the quality of medical services. As a result of timely steps taken by the Government of Bangladesh, the Covid-19 outbreak is largely controlled in Bangladesh today.

Radiant Pharmaceuticals Limited is proud to be a partner in this initiative. This achievement is due to the tireless work of all the employees of Radiant. Radiant is committed to continuing working with all such veterans in the face of such great initiatives and epidemics of the Government of Bangladesh in the future as well.

Emergency Marketing Approval / Registration:

1. Pharmaceuticals and Medical Devices Agency (PMDA) on 20 July 2021, the first country in Japan to approve the full registration and use of Casirivimab and Imdevimab in the treatment of mild to moderate symptoms.
2. The UK MHRA approved the full use and marketing of Ronapreve (Casirivimab and Imdevimab) on 20 August 2021, considering the possibility of two drugs.
3. The US Food and Drug Administration (USFDA), on 21 November 2020, approved the use of monoclonal antibody solutions under the Emergency Use Authorization (EUA).
4. The European Medicines Agency (EMA), in February 2021, gave the Emergency Use Authorization (EUA) for the use of Casirivimab and Imdevimab in the countries of the European Union.
5. SwissMedic issued an Emergency Use Authorization (EUA) for the use of Casirivimab and Imdevimab in Switzerland on 16 April 2021.
6. Central Drugs Standard Control Organization (CDSCO), DGHS, Government of India on 5 May 2021, the first country in the subcontinent to allow the use of monoclonal antibody combinations in the emergency treatment of covid patients in India.
7. Health Canada, Canada approved the use of Casirivimab and Imdevimab in the treatment of patients with mild to moderate symptoms on 10 June 2021.
8. Directorate General of Drug Administration (DGDA) on 5 September 2021 approved the use of monoclonal antibody solution in Bangladesh under the Emergency Use Authorization (EUA).
9. The World Health Organization (WHO), in the Living Guideline published on 24 September 2021, under the heading Therapeutics and COVID-19, states that Casirivimab and Imdevimab can be prescribed on the condition of being a "non-severe" patient.